DIFFUSIONSPLATTENASSAY FÜR ORITAVANCIN

European patent · EP2737077 · In force

Register entry

Publication number
EP2737077
Application number
EP12817566
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jul 26, 2012
Published
Jun 4, 2014
Granted
Nov 16, 2016
Protection ends at the latest
Jul 25, 2032
Next annual fee due
Jul 31, 2026
IPC classes
C12Q 1/18 (2006.01)
C12Q 1/04 (2006.01)
G01N 33/94 (2006.01)
Priority
US 201161511608 P 26.07.2011
US 201261642099 P 03.05.2012
PCT application
PCT/US2012/048329 26.07.2012
PCT publication
WO2013/016529 31.01.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 1, 2025

    Change

    Published in Swissreg on 01.08.2025

  2. Aug 1, 2024

    Change

    Published in Swissreg on 01.08.2024

  3. Aug 1, 2023

    Change

    Published in Swissreg on 01.08.2023

  4. Aug 1, 2022

    Change

    Published in Swissreg on 01.08.2022

  5. Nov 16, 2016

    Granted

    Published in Swissreg on 16.11.2016

Parties

Holder

The Medicines Company

8 Sylvan Way, Parsippany, NJ 07054, US

Inventor

BELLEY, Adam

Beaconsfield Québec H9W 3X6, CA

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.